Mechanisms of Adaptation Pathogenicity and Resistance in Candida glabrata

Candida glabrata has emerged as a significant opportunistic fungal pathogen, ranking as the second most common cause of candidiasis globally. Its increasing prevalence is attributed to the rise in immunocompromised populations, frequent use of indwelling medical devices, and its ability to develop resistance to antifungal drugs. C. glabrata exhibits unique adaptation strategies, including genetic diversity and plasticity, metabolic flexibility, stress response mechanisms, and biofilm formation. Its pathogenicity is characterised by adhesion factors, invasion strategies, evasion of host immune responses, and virulence factors. Notably, C. glabrata exhibits high intrinsic resistance to antifungal drugs, particularly azoles, and can rapidly acquire resistance to multiple classes of drugs. The molecular basis of drug resistance involves efflux pumps, target alterations, and mutator phenotypes caused by mismatch repair defects. Biofilm-associated resistance contributes to persistence and low therapeutic response. Diagnosing C. glabrata infections presents challenges due to its ability to evade host immune responses and the limitations of phenotypic susceptibility testing. Current treatment strategies involve antifungal therapies, combination therapies, and exploration of novel therapeutic targets. Understanding the complex interplay among C. glabrata virulence mechanisms, drug resistance, and host immune responses is crucial for developing effective management strategies and combating this emerging pathogen.